Rice Hall James & Associates LLC Acquires Shares of 689,692 Prestige Consumer Healthcare Inc. $PBH

Key Points

• Rice Hall James & Associates acquired 689,692 shares of Prestige Consumer Healthcare valued at approximately $32.6 million, giving it a 1.46% stake and making PBH one of its largest holdings.
• Institutional ownership remains nearly universal at 99.95%, with several other investment firms also increasing their positions in PBH.
• Prestige Consumer Healthcare exceeded quarterly expectations, reporting $0.98 in EPS and $265.7 million in revenue, while shares traded down 2.8%; analysts maintain a consensus “Hold” rating with a $70.75 average price target.

Rice Hall James & Associates LLC bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 689,692 shares of the company's stock, valued at approximately $32,602,000. Prestige Consumer Healthcare makes up approximately 1.6% of Rice Hall James & Associates LLC's portfolio, making the stock its 12th biggest holding. Rice Hall James & Associates LLC owned 1.46% of Prestige Consumer Healthcare at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of PBH. Leeward Investments LLC MA raised its position in shares of Prestige Consumer Healthcare by 23.3% in the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company's stock worth $23,894,000 after purchasing an additional 73,162 shares during the last quarter. Legato Capital Management LLC grew its position in Prestige Consumer Healthcare by 532.4% during the 4th quarter. Legato Capital Management LLC now owns 27,774 shares of the company's stock valued at $1,713,000 after purchasing an additional 23,382 shares during the last quarter. Brandes Investment Partners LP grew its position in Prestige Consumer Healthcare by 93.2% during the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company's stock valued at $37,430,000 after purchasing an additional 292,744 shares during the last quarter. Bessemer Group Inc. grew its position in Prestige Consumer Healthcare by 20.9% during the 1st quarter. Bessemer Group Inc. now owns 374,691 shares of the company's stock valued at $22,207,000 after purchasing an additional 64,760 shares during the last quarter. Finally, Royce & Associates LP increased its stake in Prestige Consumer Healthcare by 68.3% during the 4th quarter. Royce & Associates LP now owns 97,750 shares of the company's stock valued at $6,030,000 after purchasing an additional 39,685 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Down 2.8%

Shares of NYSE:PBH opened at $49.93 on Tuesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The company has a market cap of $2.37 billion, a P/E ratio of 13.99, a PEG ratio of 1.61 and a beta of 0.34. The stock's fifty day moving average price is $49.50 and its 200-day moving average price is $55.41.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same period last year, the company earned $0.90 EPS. Prestige Consumer Healthcare's revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PBH has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a report on Friday, May 15th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Zacks Research raised shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research report on Monday, August 10th. Finally, Oppenheimer lowered shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source